RxDoctor Payments Data

Anthony Aker

Optometrist · Panama City, FLNPI 1174555619

Payments from drug & device makers

$1,370in general payments, 2019–2025

Across 22 payments — averaging $62.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$580
  • Bausch & Lomb Americas Inc.$443
  • AbbVie$142
  • Sun Pharmaceutical Industries Inc.$112
  • Dompe US, Inc.$28
  • Novo Nordisk$20
  • plus $47 from 3 others

What the payments were for

  • Food & beverage$1,35399%
  • Education$181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,370 in reported general payments places this provider in the 60th percentile of 3,166 optometrist providers in Florida.

See all optometrist providers in Florida

Medicare billing

Part B allowed, 2024
$159,074
Medicare patients
1,173
Services billed
1,574

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost113$42,848
RestasisCyclosporine41$41,586
SimbrinzaBrinzolamide/Brimonidine Tart30$7,558
CombiganBrimonidine Tartrate/Timolol25$6,878
Latanoprost549$6,515
Cyclosporine15$6,029
Alphagan PBrimonidine Tartrate13$4,279
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol37$3,513
Brimonidine Tartrate128$3,196
Travoprost23$2,770
Loteprednol Etabonate13$1,934
Prednisolone Acetate42$1,575
Timolol Maleate136$1,548
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat81$1,534
MoxifloxacinMoxifloxacin Hcl43$779

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan, Alphagan P$142$95,591192 claims
AlconSimbrinza$580$7,55830 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$15$1,93413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 3,166 optometrist providers in Florida.

Other optometrist in Panama City

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →